US FDA Staff Backs CSL Behring Clot Disorder Therapy

January 7, 2009 |

1 min read

WASHINGTON, Jan 7 (Reuters) - CSL Ltd's proposed treatment for a rare bleeding disorder appears safe and effective enough to support approval, U.S. drug reviewers said in documents released on Wednesday.

Regulatory

Food and Drug Administration (FDA) CSL

MORE ON THIS TOPIC

Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.

Regulatory

Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter

February 10, 2026

·

2 min read

·

Tristan Manalac

Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.

Complete response letters

REGENXBIO’s Hunter Syndrome Gene Therapy Fails To Win FDA Nod

February 10, 2026

·

2 min read

·

Tristan Manalac

Red round circle with a pause button or icon against yellow background.

Gene therapy

Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study

February 9, 2026

·

1 min read

·

Tristan Manalac

Magnifying glass focusing on number 2026 with target icon on yellow background. Concept for new year focus, business goals, trends, planning, strategy, vision, success, and future opportunities.

Opinion

2025 Reshaped the FDA. What Will 2026 Hold?

February 9, 2026

·

6 min read

·